Virogin’s Pipeline

Screen Shot 2018-10-24 at 1.24.14 PM.png

Virogin is dedicated to bringing the next generation of immuno-oncolytic therapeutics to the clinic through our robust pipeline.

Our lead program, VG161, has completed the IND-enabling phase, in preparation for clinical development. The programs in our broader Synerlytic™ platform serve as the backbone of Virogin’s continued R&D of targeted and improved cancer therapeutics.